Resource Summary Report

Generated by dkNET on Sep 6, 2026

MC-38

RRID:CVCL_B288
Type: Cell Line

Proper Citation

Ubigene Cat# YC-A002, RRID:CVCL_B288

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_B288

Proper Citation: Ubigene Cat# YC-A002, RRID:CVCL_B288

Description: Cell line MC-38 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Mouse colon adenocarcinoma

Defining Citation: PMID:1149045, PMID:1255804, PMID:16320114, PMID:25277546, PMID:25428506, PMID:25434994, PMID:36969213

Comments: Caution: The authors of PubMed=25434994 indicate that they have sequenced the mitochondrial genome of the 'rat' cell line MCA38. Their submitted DNA sequence (KM820832.1) is indeed a rat sequence but is labelled as originating from 'rat isolate 406'., Miscellaneous: Comparative analysis of MC38 cells obtained from Kerafast (MC38-K) and from Leiden University Medical Center (MC38-L) shows major differences in term of mutations and mRNA expression (PubMed=36969213).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: MC-38

Synonyms: MCA-38, MCA 38, MCA38, MC38, MC-38 B/6, Mouse Colon 38, Murine Carcinoma-38, Colon-38, Colon 38, Colon38, C38

Cross References: BTO:BTO_0004163, ABM:T8291, CCRID:1101MOU-PUMC000523, ChEMBL-Cells:CHEMBL3307696, ChEMBL-Targets:CHEMBL612821, CLS:305223, Kerafast:ENH204-FP, Lonza:893, Millipore:SCC172, PubChem_Cell_line:CVCL_B288, Ubigene:YC-A002, Wikidata:Q54904168

ID: CVCL_B288

Vendor: Ubigene

Catalog Number: YC-A002

Record Creation Time: 20250130T072111+0000

Record Last Update: 20260905T184056+0000

Ratings and Alerts

No rating or validation information has been found for MC-38.

No alerts have been found for MC-38.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 1489 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Wang X, et al. (2026) Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. Cancer cell, 44(3), 658.

Liang X, et al. (2026) Colorectal cancer-derived osteopontin rewires macrophages into a pro-metastatic M2 state via the PI3K/AKT/CSF1-CSF1R axis. Cell death discovery, 12(1), 92.

Gruber DR, et al. (2026) Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models. Molecular cancer therapeutics, 25(3), 457.

Lim SK, et al. (2026) Targeted computational design of an interleukin-7 superkine with enhanced folding efficiency and immunotherapeutic efficacy. eLife, 14.

Chen W, et al. (2026) USP35 Acts as a Deubiquitinating Enzyme for ID3 to Promote Immune Escape in Colorectal Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e16588.

Mödl B, et al. (2026) TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis. Cancer research, 86(1), 80.

Jiang Y, et al. (2026) Ultrasmall Au10-12 Nanoclusters: A Novel Platform for 223Ra-Targeted Tumor ?-Therapy. Exploration (Beijing, China), 6(2), 70144.

Mosley SR, et al. (2026) Cytosolic DNA structures produced by mismatch repair deficiency coordinate anti-tumor immunity in colorectal cancer. Cell reports, 45(3), 117012.

Cornelius P, et al. (2026) Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth. Frontiers in oncology, 16, 1751681.

Fu J, et al. (2026) mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy. Cell reports. Medicine, 7(4), 102706.

Tao G, et al. (2026) Radiation-induced MYB reduction unleashes TIM-3 expression in NK cells to attenuate antitumor immunity in colorectal cancer. Journal of translational medicine, 24(1).

Nie H, et al. (2026) GBP2 enhances anti-PD-L1 response in colorectal cancer via GSDMD-mediated YAP nuclear translocation by non-pyroptotic. Oncogene, 45(25), 2452.

Malagola E, et al. (2026) Loss of proton-sensing TDAG8 increases tumor progression in mouse models of colon cancer. Molecular oncology.

Mizuno N, et al. (2026) Characterization of a transmembrane-activating STING agonist using genetically humanized mice. Cell reports, 45(6), 117475.

Lin Y, et al. (2026) Integrin CD11b/CD18 reprograms macrophage polarization by suppressing ERK/STAT3 signaling to enhance antitumor immunity in colitis-associated colorectal cancer. Journal for immunotherapy of cancer, 14(6).

Wang H, et al. (2026) ZNF296 Drives Immune Evasion in Epithelial Cancers by Repressing Immune Stimulatory Genes. Cancer research, 86(1), 116.

Zhang B, et al. (2026) Immunometabolic Rewiring of Dendritic Cells to Overcome Glutamine-Driven Immune Suppression in Colorectal Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(5), e13986.

Zhang J, et al. (2026) Tumor-associated macrophages educated by IGSF9 exhibit a senescence-associated secretory phenotype to promote tumor immune escape. Journal for immunotherapy of cancer, 14(1).

Napoleon JV, et al. (2026) A Folate Receptor ?-Targeted TLR7 Agonist Significantly Augments Checkpoint Inhibitor Potencies by Reprogramming Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells. Journal of medicinal chemistry, 69(5), 5901.

Pan D, et al. (2026) DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy. Cancer research, 86(12), 3026.